These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25966006)

  • 1. Tiered approach to metabolite quantification: regional practices reviewed by Japan Bioanalysis Forum discussion group.
    Niwa M; Uchimura T; Koseki N; Satsukawa M; Hashimoto Y; Mayumi T; Yasuda Y; Yokoi H
    Bioanalysis; 2015; 7(8):935-8. PubMed ID: 25966006
    [No Abstract]   [Full Text] [Related]  

  • 2. Best practices for metabolite quantification in drug development: updated recommendation from the European Bioanalysis Forum.
    Timmerman P; Blech S; White S; Green M; Delatour C; McDougall S; Mannens G; Smeraglia J; Williams S; Young G
    Bioanalysis; 2016 Jun; 8(12):1297-305. PubMed ID: 27217058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Best practices in a tiered approach to metabolite quantification: views and recommendations of the European Bioanalysis Forum.
    Timmerman P; Anders Kall M; Gordon B; Laakso S; Freisleben A; Hucker R
    Bioanalysis; 2010 Jul; 2(7):1185-94. PubMed ID: 21083233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Giving consideration to scientific validation in Japanese drug application by Japan Bioanalysis Forum discussion group.
    Koseki N; Ashizawa H; Ishii T; Uchimura T; Ono K; Kuriyama S; Toda A; Soejima K; Nakai N; Nishimura N; Mayumi T; Yasuda Y; Yamakawa T; Niwa M
    Bioanalysis; 2017 Jul; 9(13):963-968. PubMed ID: 28708436
    [No Abstract]   [Full Text] [Related]  

  • 5. A tiered approach to address regulatory drug metabolite-related issues in drug development.
    Ma S; Chowdhury SK
    Bioanalysis; 2014 Mar; 6(5):587-90. PubMed ID: 24620798
    [No Abstract]   [Full Text] [Related]  

  • 6. An industry perspective on tiered approach to the investigation of metabolites in drug development.
    Huskey SE; Li W; Mangold JB; Flarakos J
    Bioanalysis; 2014 Mar; 6(5):617-28. PubMed ID: 24620804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A community of practice approach to bioanalysis delivery: the role of the Preclinical Bioanalysis and Toxicokinetics department at AstraZeneca.
    Wilson A; Silvester S; Woods K
    Bioanalysis; 2014 May; 6(10):1329-37. PubMed ID: 24958117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioanalysis of chiral compounds during drug development using a tiered approach.
    Jian W; Edom RW; Huang MQ; Weng N
    Bioanalysis; 2014 Mar; 6(5):629-39. PubMed ID: 24620805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug bioanalysis and biomarker discovery at the Commissariat à l'énergie atomique et aux énergies alternatives.
    Ezan E; Becher F; Benech H; Fenaille F; Junot C; Mabondzo A; Pruvost A
    Bioanalysis; 2010 Apr; 2(4):713-7. PubMed ID: 21083268
    [No Abstract]   [Full Text] [Related]  

  • 10. A novel LC-MS approach for the detection of metabolites in DMPK studies.
    Plumb RS; Mather J; Little D; Rainville PD; Twohig M; Harland G; Kenny DJ; Nicholson JK; Wilson ID; Kass IJ
    Bioanalysis; 2010 Oct; 2(10):1767-78. PubMed ID: 21083328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of 'post bioanalysis phase' in bioanalysis: is GMP creeping into GLP?
    Yadav MS; Shrivastav PS
    Bioanalysis; 2015; 7(1):15-20. PubMed ID: 25558932
    [No Abstract]   [Full Text] [Related]  

  • 12. Metabolomics and biochemical profiling in drug discovery and development.
    Watkins SM; German JB
    Curr Opin Mol Ther; 2002 Jun; 4(3):224-8. PubMed ID: 12139307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survey on the tiered approach for Japanese bioanalysts operated by Japan bioanalysis forum DG2014-09.
    Niwa M; Koseki N; Hashimoto Y; Mayumi T; Nishimura N; Satsukawa M; Uchimura T; Yasuda Y; Yokoi H
    Bioanalysis; 2016; 8(2):93-8. PubMed ID: 26653036
    [No Abstract]   [Full Text] [Related]  

  • 14. Are meaningful predictions of toxicological outcomes in clinical trials based on in vitro diagnostics of preclinical drug candidates possible?
    Kroll F; Dreger M
    Future Med Chem; 2010 Nov; 2(11):1613-7. PubMed ID: 21428831
    [No Abstract]   [Full Text] [Related]  

  • 15. How the bioanalytical scientist plays a key role in interdisciplinary project teams in the development of biotherapeutics - a reflection of the European Bioanalysis Forum.
    Dudal S; Staack RF; Stoellner D; Fjording MS; Vieser E; Pascual MH; Brudny-Kloeppel M; Golob M
    Bioanalysis; 2014 May; 6(10):1339-48. PubMed ID: 24958118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conference report: Inaugural Applied Pharmaceutical Analysis: India 2010 conference.
    Ramanathan R; Chaudhary A
    Bioanalysis; 2010 Jul; 2(7):1181-4. PubMed ID: 21083232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-resolution mass spectrometry will dramatically change our drug-discovery bioanalysis procedures.
    Korfmacher W
    Bioanalysis; 2011 Jun; 3(11):1169-71. PubMed ID: 21649491
    [No Abstract]   [Full Text] [Related]  

  • 18. Conference report: European Bioanalysis Forum.
    Abbott RW; Brudny-Kloeppel M
    Bioanalysis; 2009 May; 1(2):273-6. PubMed ID: 21083164
    [No Abstract]   [Full Text] [Related]  

  • 19. A reflection on fit-for-purpose metabolite investigation at different stages of drug development.
    Leclercq L
    Bioanalysis; 2014 Mar; 6(5):591-4. PubMed ID: 24620799
    [No Abstract]   [Full Text] [Related]  

  • 20. Importance of metabolite testing in regulated bioanalysis.
    Garofolo F; Savoie N; Bergeron A; Amestoy C; Lefebvre M; Caillé L; Furtado M; Menard C
    Bioanalysis; 2010 Jul; 2(7):1171-4. PubMed ID: 21083229
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.